It all seems to point to iffy IP. Science Officer with two companies. Baylor as Investigator. "Product of Nature" ruling. Shareholders really must insist on an IP presentation with Q&A.
On a side note, has anything "biotech" that Dart ever touched made it?
News 
Market Data 
Discover 
